Antipsychotic management in general practice: serial cross-sectional study (2011-2020) - Woodall, Alan; Gampel, Alex; Collins, Huw; Walker, Lauren E; Mair, Frances S; Sheard, Sally; Symon, Pyers; Buchan, Iain (medRxiv, 2024)
Background Long-term use of antipsychotics confers increased risk of cardiometabolic disease. Ongoing need should be reviewed regularly by psychiatrists.Aim To explore trends in antipsychotic management in general practice, and proportions of patients prescribed antipsychotics receiving psychiatrist review.Design and Setting A serial cross-sectional study using linked general practice and hospital data in Wales (2011-2020).Method Participants were adults (>=18 years) registered with general practices in Wales. Outcome measures were prevalence of patients receiving >=6 antipsychotic prescriptions annually, proportion of patients prescribed antipsychotics receiving annual psychiatrist review, and proportion of patients prescribed antipsychotics registered on UK Serious Mental Illness, Depression and/or Dementia registers, or not on any of these registers.Results Prevalence of adults prescribed long-term antipsychotics increased from 1.06% (95%CI 1.04 to 1.07%) in 2011 to 1.45% (95%CI 1.43 to 1.46%) in 2020. The proportion receiving annual psychiatrist review decreased from 59.6% (95%CI 58.9 to 60.4%) in 2011 to 52.0% (95C%CI 51.4 to 52.7%) in 2020. The proportion of antipsychotics prescribed to patients not on the Serious Mental Illness register increased from 50% (95%CI 49 to 51%) in 2011 to 56% (95%CI 56 to 57%) by 2020.Conclusions Prevalence of long-term antipsychotic use is increasing. More patients are managed by general practitioners without psychiatrist review and are not on monitored disease registers; they thus may be less likely to undergo cardiometabolic monitoring and miss opportunities to optimise or deprescribe antipsychotics. These trends pose risks for patients and need to be addressed urgently.How this fits in Antipsychotics are effective treatments for serious mental illness, but long-term use increases the risk of cardiometabolic disease, therefore ongoing use should be reviewed regularly. There is increasing use of these medications for non-psychotic mental illness by psychiatrists who then discharge patients to sole care by GPs, often for patients who are not captured on disease registers that automate recall for cardiometabolic risk monitoring. This study demonstrates a rising burden of long-term antipsychotic prescribing in general practice, with nearly half of all adult patients not under annual psychiatrist review, and only 44% of long-term antipsychotic prescriptions being issued to patients coded on the Quality and Outcomes Framework (QOF) Serious Mental Illness register. This means many patients taking antipsychotics may be missed for cardiometabolic screening and expert review. Policy changes are required to ensure regular effective review and monitoring to prevent increasing morbidity and early mortality for patients prescribed long-term antipsychotics.Competing Interest StatementAW, LEW, IB, and FSM receive funding from the NIHR DynAIRx project(NIHR 203986) investigating the use of artificial intelligence to optimize prescribing. IB has acted as an advisor to Astrazeneca plc, on behalf of University of Liverpool.Funding StatementAW was awarded an Health Care Research Wales Research Time Award (Grant number: NHS-RTA-21-02) to undertake this work. IB is funded by a National Institute of Health Research (NIHR) Senior Investigator award (NIHR 205131).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:SAIL Databank Information Governance Research Panel (of Swansea University, Wales, UK) gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors https://github.com/alanwoodall/AMP-Epidemiology